Discover Community Create You

Loading publication...

Noodle always counts identifier-free feature events for service operation. With your permission, Google Analytics can also estimate audience and engagement. Search text, publication identifiers, cookies, IP addresses and browser fingerprints are never included in Noodle's first-party event counters.

Privacy details

Article

VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide.

British journal of cancer - 20 Aug 2013

Orlandi P, Fontana A, Fioravanti A, Di Desidero T, Galli L, Derosa L, Canu B, Marconcini R, Biasco E, Solini A, Francia G, Danesi R, Falcone A, Bocci G

Abstract excerpt

BACKGROUND: No data are available on the pharmacogenetics of metronomic chemotherapy in prostate cancer. The aim of this study was to evaluate the association between VEGF-A sequence variants and prostate-specific antigen (PSA) progression, progression-free survival (PFS) and overall survival (OS), in advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide (CTX), celecoxib...

Read the complete abstract on PubMed

Topics

Share this publication in a Topic to start or enrich a Post.

Share to Angiogenesis Inhibitors
Share to Antineoplastic Agents, Alkylating

Methodology Data sources Editorial policy Privacy About Contact Helena Bioinformatics

Share to Antineoplastic Agents, Hormonal

Share to Cyclooxygenase 2 Inhibitors

Share to Cyclophosphamide

Share to Dexamethasone

Share to Kallikreins

Share to Prostate-Specific Antigen

Source

Open in PubMed Open full text

Identifiers

PMID: 23860526
DOI: 10.1038/bjc.2013.398
PMCID: PMC3749570

Provenance

PubMed metadata and Literature Corpus relationships. Corpus snapshot updated 7 Sept 2026. Manifest publication-graph-cohort-2026-09-08.1.

Source receipt: pubmed, retrieved 7 Sept 2026.

Related research

Semantic proximity does not establish scientific evidence.

Research trail→

Click a neighbor to travelStep 1 · 12 closest

VEGF-A polymorphisms predict progression-free survival among advanced castration-resistant prostate cancer patients treated with metronomic cyclophosphamide.PMID 23860526Read ↗

Connecting Gene Variation to Treatment Outcomes in Metastatic Castration-Resistant Prostate Adenocarcinoma: Insights into Second-Generation Androgen Receptor Axis-Targeted Therapies.Semantic proximity Read ↗

Circulating-tumor DNA as predictor of enzalutamide response post-abiraterone treatment in metastatic castration-resistant prostate cancer.Semantic proximity Read ↗

Single-nucleotide polymorphism associations with efficacy and toxicity in metastatic castration-resistant prostate cancer treated with cabazitaxel.Semantic proximity Read ↗

Clonal Hematopoiesis and Clinical Outcomes in Metastatic Castration-Resistant Prostate Cancer Patients Given Androgen Receptor Pathway Inhibitors (Alliance A031201).Semantic proximity Read ↗

Circulating tumor DNA alterations in patients with metastatic castration‐resistant prostate cancerSemantic proximity Read ↗

The influence of single-nucleotide polymorphisms on overall survival and toxicity in cabazitaxel-treated patients with metastatic castration-resistant prostate cancer.Semantic proximity Read ↗

Molecular markers in sex hormone pathway genes associated with the efficacy of androgen-deprivation therapy for prostate cancer.Semantic proximity Read ↗

<i>HSD3B1</i> genotype among metastatic castration-resistant prostate cancer patients: pharmacodynamics and clinical outcomes after treatment with abiraterone plus prednisoneSemantic proximity Read ↗

HSD3B1 and Response to a Nonsteroidal CYP17A1 Inhibitor in Castration-Resistant Prostate Cancer.Semantic proximity Read ↗

CYP17A1 polymorphisms and clinical outcome of castration-resistant prostate cancer patients treated with abiraterone.Semantic proximity Read ↗

Molecular Profile Changes in Patients with Castrate-Resistant Prostate Cancer Pre- and Post-Abiraterone/Prednisone TreatmentSemantic proximity Read ↗

Treatment with abiraterone and enzalutamide does not overcome poor outcome from metastatic castration-resistant prostate cancer in men with the germline homozygous HSD3B1 c.1245C genotype.Semantic proximity Read ↗

⌁Select a neighboring publication to make it the new centre.